USCA RIA’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | $6.65M | Buy |
133,682
+7,661
| +6% | +$368K | 0.4% | 63 |
|
|
2021
Q1 | $5.62M | Buy |
126,021
+11,743
| +10% | +$533K | 0.37% | 74 |
|
|
2020
Q4 | $5.26M | Buy |
114,278
+9,296
| +9% | +$427K | 0.37% | 61 |
|
|
2020
Q3 | $4.94M | Buy |
104,982
+11,100
| +12% | +$556K | 0.39% | 57 |
|
|
2020
Q2 | $4.79M | Buy |
93,882
+14,339
| +18% | +$736K | 0.42% | 53 |
|
|
2020
Q1 | $3.77M | Buy |
79,543
+32,303
| +68% | +$1.72M | 0.44% | 54 |
|
|
2019
Q4 | $2.77M | Sell |
47,240
-32,142
| -40% | -$1.79M | 0.25% | 130 |
|
|
2019
Q3 | $4.24M | Buy |
79,382
+8,719
| +12% | +$449K | 0.42% | 68 |
|
|
2019
Q2 | $3.54M | Buy |
70,663
+12,073
| +21% | +$606K | 0.36% | 83 |
|
|
2019
Q1 | $3.06M | Buy |
58,590
+2,160
| +4% | +$108K | 0.33% | 101 |
|
|
2018
Q4 | $2.69M | Buy |
56,430
+9,098
| +19% | +$448K | 0.36% | 95 |
|
|
2018
Q3 | $2.38M | Buy |
47,332
+10,512
| +29% | +$534K | 0.24% | 133 |
|
|
2018
Q2 | $1.85M | Sell |
36,820
-1,329
| -3% | -$66.9K | 0.2% | 155 |
|
|
2018
Q1 | $1.86M | Sell |
38,149
-14,474
| -28% | -$674K | 0.21% | 144 |
|
|
2017
Q4 | $2.33M | Buy |
52,623
+27,538
| +110% | +$1.27M | 0.26% | 115 |
|
|
2017
Q3 | $1.35M | Hold |
25,085
| – | – | 0.17% | 165 |
|
|
2017
Q2 | $1.35M | Buy |
25,085
+1,071
| +4% | +$57.1K | 0.17% | 166 |
|
|
2017
Q1 | $1.27M | Buy |
24,014
+2,382
| +11% | +$121K | 0.19% | 158 |
|
|
2016
Q4 | $1.04M | Buy |
21,632
+5,095
| +31% | +$252K | 0.16% | 165 |
|
|
2016
Q3 | $892K | Buy |
16,537
+3,452
| +26% | +$189K | 0.15% | 169 |
|
|
2016
Q2 | $709K | Buy |
13,085
+3,019
| +30% | +$159K | 0.12% | 191 |
|
|
2016
Q1 | $510K | Buy |
10,066
+1,544
| +18% | +$76.9K | 0.09% | 207 |
|
|
2015
Q4 | $430K | Buy |
8,522
+2,140
| +34% | +$109K | 0.09% | 220 |
|
|
2015
Q3 | $307K | Buy |
6,382
+2,018
| +46% | +$105K | 0.08% | 257 |
|
|
2015
Q2 | $227K | Buy |
+4,364
| New | +$246K | 0.06% | 302 |
|
|
2014
Q4 | – | Sell |
-3,681
| Closed | -$212K | – | 336 |
|
|
2014
Q3 | $212K | Buy |
+3,681
| New | +$226K | 0.06% | 285 |
|
|
2013
Q4 | – | Sell |
-5,026
| Closed | -$315K | – | 263 |
|
|
2013
Q3 | $315K | Buy |
5,026
+240
| +5% | +$15.4K | 0.14% | 174 |
|
|
2013
Q2 | $299K | Buy |
+4,786
| New | +$304K | 0.15% | 169 |
|
Other funds holding GSK
BCIM
USCA RIA's GSK Position: Q2 2021 in Review
USCA RIA increased its GSK (GSK) stake by 6.1% in Q2 2021, buying an estimated $368K and bringing the position to 133,682 shares worth $6.65M. The position accounts for 0.4% of the portfolio, ranked #63.
USCA RIA first reported a position in GSK in Q2 2013 and has held it in 28 quarters since. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.
- USCA RIA held 133,682 shares of GSK worth $6.65M as of Q2 2021.
- USCA RIA bought 7,661 GSK shares in Q2 2021, an estimated $368K.
- GSK made up 0.4% of USCA RIA's portfolio in Q2 2021, its #63 holding.
- USCA RIA first reported a position in GSK in Q2 2013 and has held it in 28 quarters since.
- 798 funds tracked by Wall St. Rank held GSK as of Q2 2021.
Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.